期刊
BLOOD REVIEWS
卷 48, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2021.100806
关键词
Acute myeloid leukemia; AML; CRh; CRi; CRp; Incomplete; Partial; Remission; Response
类别
资金
- NCI's Cancer Clinical Investigator Team Leadership Award (CCITLA)
- National Cancer Institute of the National Institutes of Health [P30 CA016359]
This article discusses the evolution of complete remission (CR) and less than CR responses in acute myeloid leukemia treatment, highlighting the need for a reevaluation of the clinical value of less than CR responses, and calling for the incorporation of measurable residual disease (MRD) techniques into future clinical trials.
Complete remission (CR) has long been the critical therapeutic response in acute myeloid leukemia (AML). However, less than CR responses have been and continue to be proposed to define clinically meaningful posttherapy outcomes. These responses include CR with incomplete recovery (CRi), CR with incomplete platelet recovery (CRp) and, most recently, CR with partial hematologic recovery (CRh), which has been introduced and subsequently used for regulatory approval. However, the clinical benefits associated with less than CR responses have primarily been evaluated in the context of intensive therapies. In an era with sophisticated measurable residual disease (MRD) assessments, including flow-based, cytogenetic and molecular techniques, and an increase in targeted, non-intensive therapies, the clinical value of responses that are less than CR must be reevaluated. Improvements in the rate of CR has not always led to improvements in OS among older patients. As such, MRD techniques might help define a more stringent response criterion (MRD-negative CR) that might better correlate with OS and should be incorporated in future clinical trials. Here we discuss the evolution of CR and less than CR responses, data regarding their clinical benefits, and considerations relevant to response assessments with newer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据